JP2022539569A5 - - Google Patents

Info

Publication number
JP2022539569A5
JP2022539569A5 JP2021577896A JP2021577896A JP2022539569A5 JP 2022539569 A5 JP2022539569 A5 JP 2022539569A5 JP 2021577896 A JP2021577896 A JP 2021577896A JP 2021577896 A JP2021577896 A JP 2021577896A JP 2022539569 A5 JP2022539569 A5 JP 2022539569A5
Authority
JP
Japan
Prior art keywords
promoter
dual
vector system
grna
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577896A
Other languages
English (en)
Japanese (ja)
Other versions
JP7724721B2 (ja
JP2022539569A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040608 external-priority patent/WO2021003337A1/en
Publication of JP2022539569A publication Critical patent/JP2022539569A/ja
Publication of JP2022539569A5 publication Critical patent/JP2022539569A5/ja
Application granted granted Critical
Publication of JP7724721B2 publication Critical patent/JP7724721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577896A 2019-07-03 2020-07-02 遺伝子置換のための組成物および方法 Active JP7724721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870488P 2019-07-03 2019-07-03
US62/870,488 2019-07-03
PCT/US2020/040608 WO2021003337A1 (en) 2019-07-03 2020-07-02 Compositions and methods for gene replacement

Publications (3)

Publication Number Publication Date
JP2022539569A JP2022539569A (ja) 2022-09-12
JP2022539569A5 true JP2022539569A5 (cg-RX-API-DMAC7.html) 2023-06-30
JP7724721B2 JP7724721B2 (ja) 2025-08-18

Family

ID=74101132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577896A Active JP7724721B2 (ja) 2019-07-03 2020-07-02 遺伝子置換のための組成物および方法

Country Status (6)

Country Link
US (1) US12667628B2 (cg-RX-API-DMAC7.html)
EP (1) EP3994254A4 (cg-RX-API-DMAC7.html)
JP (1) JP7724721B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020298549B2 (cg-RX-API-DMAC7.html)
CA (1) CA3145289A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021003337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4322975A4 (en) * 2021-04-14 2025-03-26 Capsida, Inc. PLASMIDS AND PROCESSES FOR PRODUCING ADENO-ASSOCIATED VIRUSES
CN113584082B (zh) * 2021-06-22 2023-07-25 复旦大学附属眼耳鼻喉科医院 CRISPR/Cas9基因编辑系统及其在制备治疗遗传性感音神经性聋的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
US8394604B2 (en) 2008-04-30 2013-03-12 Paul Xiang-Qin Liu Protein splicing using short terminal split inteins
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
US9758781B2 (en) * 2014-09-30 2017-09-12 University Of Iowa Research Foundation Methods to prevent and treat autosomal dominant non-syndromic hearing loss
EP3230452B1 (en) 2014-12-12 2025-06-11 The Broad Institute, Inc. Dead guides for crispr transcription factors
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
CA2979120A1 (en) 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
JP6851319B2 (ja) * 2015-04-27 2021-03-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
CN111698975A (zh) 2017-02-06 2020-09-22 儿童医疗中心有限公司 将核酸递送至耳蜗和前庭细胞的材料和方法
MA47820A (fr) 2017-03-10 2020-01-15 Genethon Traitement de la glycogénose de type iii
JP7430652B2 (ja) 2018-03-05 2024-02-13 ザ チルドレンズ メディカル センター コーポレーション 蝸牛および前庭細胞に核酸を送達するための組成物および方法
JP2021530227A (ja) 2018-07-13 2021-11-11 アコーオス インコーポレイテッド 非症候性感音性聴力喪失の治療方法
CA3116606A1 (en) 2018-10-15 2020-04-23 Fondazione Telethon Intein proteins and uses thereof
US20230090778A1 (en) 2020-02-07 2023-03-23 The Children's Medical Center Corporation Large gene vectors and delivery and uses thereof

Similar Documents

Publication Publication Date Title
JP7860169B2 (ja) 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
US20240076698A1 (en) Methods and compositions for modulating a genome
AU2019227726B2 (en) Novel adeno-associated virus (AAV) vectors, aav vectors having reduced capsid deamidation and uses therefor
CN103314106B (zh) 修饰的人类U1snRNA分子、编码修饰的人类U1snRNA分子的基因、包括该基因的表达载体及其在基因治疗中的用途
JP2020513814A (ja) Crispr cas9免疫ステルス(immune stealth)の操作
US10016514B2 (en) Polynucleotides, vectors and methods for insertion and expression of transgenes
JP7123982B2 (ja) 肝臓において目的のタンパク質を発現するためのプラットフォーム
US9669109B1 (en) Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
TW202320810A (zh) Pah調節組合物及方法
CN113195721A (zh) 治疗α-1抗胰蛋白酶缺乏症的组合物和方法
US20220071981A1 (en) Compositions and methods for hemoglobin production
US20230174958A1 (en) Crispr-inhibition for facioscapulohumeral muscular dystrophy
WO2023225662A2 (en) Protac-cid systems for use in multiplex gene regulation
KR20260048590A (ko) 유전자 편집 시스템 및 그 용도
WO2025014986A2 (en) Therapy for alpha-1 antitrypsin deficiency
US20230220361A1 (en) Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells
WO2025147949A1 (zh) 基因编辑系统及其应用
WO2023214512A1 (ja) 人工rna分子
US20250163474A1 (en) Systems, methods, and compositions for targeted gene manipulation and uses thereof
WO2026065401A1 (zh) 一种用于调控SCN1A基因mRNA和蛋白表达的方法和化合物
US20230045199A1 (en) Compositions and methods for hemoglobin production
HK40130495A (en) Novel adeno-associated virus (aav) vector, aav vector with reduced capsid deamidation, and use thereof
JP2024538769A5 (cg-RX-API-DMAC7.html)
HK40057846A (en) Compositions and methods for treating alpha-1 antitrypsin deficiencey
EA049701B1 (ru) Новые векторы на основе аденоассоциированного вируса (aav), векторы aav, со сниженным дезамидированием капсида, а также их применение